Case Report: Apatinib Combined with Neoadjuvant Therapy for Primary Squamous Cell Carcinoma of the Breast: a Case Report

Overview

Journal Front Pharmacol

Date 2023 May 30

PMID 37251309

Authors

Fangfang Gao

Jingtai Li

Haoran Liao

Pingming Fan

Minjian Wang

Yu Liu

Linwei Ding

Guankui Du

Affiliations

Soon will be listed here.

Abstract

Primary squamous cell carcinoma of the breast is a rare subtype of carcinoma of chemosis for which there is no effective chemotherapy regimen. Breast squamous cell carcinoma is usually "triple negative", with poor chemotherapy effects and poor prognosis. Here, we report a successful case of primary breast squamous cell carcinoma treated with apatinib. The patient was treated with 2 cycles of apatinib. The efficacy was evaluated as partial remission, and a sublesion of approximately 4 cm fell off.

References

Lei R, Miao L . Primary squamous cell carcinoma of the breast: report of two cases with HER2 overexpression. Cancer Biol Ther. 2020; 21(12):1081-1086. PMC: 7747679. DOI: 10.1080/15384047.2020.1838033. View

Liu J, Li Y, Li Q, Liang D, Wang Q, Liu Q . Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in advanced triple-negative breast cancer patients. Breast Cancer Res Treat. 2021; 186(3):687-697. DOI: 10.1007/s10549-021-06128-4. View

Yang J, Zhou D, Wu Y, Zhu Y, Lin Z, Zhang T . The prognostic value of baseline hematological parameters of peripheral blood in metastatic gastric cancer treated with apatinib. J Cancer. 2022; 13(1):15-20. PMC: 8692676. DOI: 10.7150/jca.65339. View

Cao Y, Yue Y, Zhou X, Luo J, Zeng X, Dong J . Change of HER2 status during disease recurrence predicts good prognosis for primary squamous cell carcinoma of the breast: A case report. Medicine (Baltimore). 2019; 98(9):e14654. PMC: 6831174. DOI: 10.1097/MD.0000000000014654. View

Seddik Y, Brahmi S, Afqir S . Primary squamous cell carcinoma of the breast: a case report and review of literature. Pan Afr Med J. 2016; 20:152. PMC: 4919683. DOI: 10.11604/pamj.2015.20.152.6188. View

Tang D, Ma J, Chu Z, Wang X, Zhao W, Zhang Q . Apatinib-induced NF-κB inactivation sensitizes triple-negative breast cancer cells to doxorubicin. Am J Transl Res. 2020; 12(7):3741-3753. PMC: 7407711. View

Qi W, Cao L, Xu C, Chen J . Lumpectomy Combined with Adjuvant Radiotherapy Could Be a Treatment Option for Primary Squamous Cell Carcinoma of the Breast. J Oncol. 2021; 2021:2497227. PMC: 8660218. DOI: 10.1155/2021/2497227. View

Shrestha S, Shakya P, Kharel S, Dhakal H, Singh M, Shrestha A . Primary squamous cell carcinoma of the breast in a young female- A rare ailment. Clin Case Rep. 2021; 9(5):e04214. PMC: 8142402. DOI: 10.1002/ccr3.4214. View

Wang X, Zhang L, Luo J, Jin K, Yang Z, Meng J . Postoperative radiotherapy improves overall survival in patients with primary squamous cell carcinoma of the breast. Asia Pac J Clin Oncol. 2020; 17(6):454-461. DOI: 10.1111/ajco.13466. View

10.

Liu J, Yu Y, Sun J, He S, Wang X, Yin J . Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast. Breast Cancer Res Treat. 2014; 149(1):133-40. DOI: 10.1007/s10549-014-3224-z. View

11.

Anne N, Sulger E, Pallapothu R . Primary squamous cell carcinoma of the breast: a case report and review of the literature. J Surg Case Rep. 2019; 2019(6):rjz182. PMC: 6565815. DOI: 10.1093/jscr/rjz182. View

12.

Feng H, Jin Z, Liang J, Zhao Q, Zhan L, Yang Z . FOXK2 transcriptionally activating VEGFA induces apatinib resistance in anaplastic thyroid cancer through VEGFA/VEGFR1 pathway. Oncogene. 2021; 40(42):6115-6129. DOI: 10.1038/s41388-021-01830-5. View

13.

Zhang Y, Zhou L, Xu Y, Zhou J, Jiang T, Wang J . Targeting SMYD2 inhibits angiogenesis and increases the efficiency of apatinib by suppressing EGFL7 in colorectal cancer. Angiogenesis. 2022; 26(1):1-18. DOI: 10.1007/s10456-022-09839-4. View

14.

Yoneto T, Hasumi K, Yoshimoto T, Takahashi N, Takeda Y . Case report: two cases of extremely rare primary pure squamous cell carcinoma of the breast. Medicine (Baltimore). 2018; 97(37):e12340. PMC: 6156038. DOI: 10.1097/MD.0000000000012340. View

15.

Chen J, Feng L, Sheng Q, Li L . Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple-Negative Breast Cancer. Evid Based Complement Alternat Med. 2021; 2021:8720679. PMC: 8528587. DOI: 10.1155/2021/8720679. View

16.

Zeng T, Sun C, Liang Y, Yang F, Yan X, Bao S . A Real-World Multicentre Retrospective Study of Low-Dose Apatinib for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. Cancers (Basel). 2022; 14(17). PMC: 9454649. DOI: 10.3390/cancers14174084. View

17.

Tsung S . Primary pure squamous cell carcinoma of the breast might be sensitive to Cisplatin-based chemotherapy. Case Rep Oncol. 2012; 5(3):561-5. PMC: 3492996. DOI: 10.1159/000343745. View

18.

Wang H, Su W, Lowe S, Zhou Z, Bentley R, Zhou Q . Association of Apatinib and Breast Cancer: A systematic review and meta-analysis. Surg Oncol. 2022; 44:101818. DOI: 10.1016/j.suronc.2022.101818. View

19.

Goel D, Rana C, Babu S, Ramakant P . Primary squamous cell carcinoma, breast: A challenging diagnosis. Cancer Rep (Hoboken). 2021; 4(5):e1391. PMC: 8551986. DOI: 10.1002/cnr2.1391. View

20.

Zheng Z, Liu Z, Zhang H, Guo X, Jia X, Wang J . Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study. Front Pharmacol. 2022; 13:894016. PMC: 9152289. DOI: 10.3389/fphar.2022.894016. View